SMO ClinPlus Co. Ltd. - Asset Resilience Ratio
SMO ClinPlus Co. Ltd. (301257) has an Asset Resilience Ratio of 14.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 301257 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how SMO ClinPlus Co. Ltd.'s Asset Resilience Ratio has changed over time. See shareholders equity of SMO ClinPlus Co. Ltd. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SMO ClinPlus Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SMO ClinPlus Co. Ltd. market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥210.73 Million | 14.36% |
| Total Liquid Assets | CN¥210.73 Million | 14.36% |
Asset Resilience Insights
- Moderate Liquidity: SMO ClinPlus Co. Ltd. has 14.36% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
SMO ClinPlus Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare SMO ClinPlus Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.19% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 0.75% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for SMO ClinPlus Co. Ltd. (2022–2024)
The table below shows the annual Asset Resilience Ratio data for SMO ClinPlus Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.02% | CN¥400.58 Million ≈ $58.62 Million |
CN¥1.43 Billion ≈ $209.20 Million |
-2.79pp |
| 2023-12-31 | 30.81% | CN¥421.14 Million ≈ $61.63 Million |
CN¥1.37 Billion ≈ $200.01 Million |
+19.06pp |
| 2022-12-31 | 11.75% | CN¥136.38 Million ≈ $19.96 Million |
CN¥1.16 Billion ≈ $169.85 Million |
-- |
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Shanghai, China.